On-demand video webcast now available hereISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a ...
FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...
Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Hyderabad: Aurobindo Pharma has announced that the United States Food and Drug Administration (US FDA) had conducted an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results